Trial Profile
Phase 1 Randomized, Blinded, Placebo-Controlled Study of Single Ascending Doses of BIIB063 in Healthy Volunteers
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs BIIB 063 (Primary) ; BIIB 063 (Primary)
- Indications Sjogren's syndrome
- Focus Adverse reactions; First in man; Pharmacodynamics
- Sponsors Biogen
- 08 Nov 2017 Results presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting
- 17 Apr 2017 Status changed from suspended to discontinued due to pending additional preclinical safety findings in non-human primates.
- 24 Aug 2016 Planned End Date changed from 1 Jul 2016 to 1 Jul 2017.